Forxiga safety under the microscope: Real-World data from 1,000 patients
NCT ID NCT07210307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracked over 1,000 adults with type 2 diabetes in Vietnam who were prescribed dapagliflozin (Forxiga) as part of routine care. Researchers monitored side effects and serious events over 24 weeks to confirm the drug's safety in real-world use. The goal was to support the drug's continued approval in Vietnam.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dapagliflozin (Forxiga)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY OUTCOMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HCMC Heart Institute
Ho Chi Minh City, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections